TBI-223

TBI-223 is a novel orally bioavailable oxazolidinone antibiotic under clinical development for the treatment of tuberculosis (TB). It acts as an inhibitor of the bacterial 50S ribosomal subunit, thereby blocking protein synthesis in Mycobacterium tuberculosis and other Gram-positive bacteria. Preclinical studies show that it has potent activity against both drug-sensitive and drug-resistant TB strains, as well as efficacy in mouse models of TB infection. Compared to linezolid, another oxazolidinone used for TB therapy, TBI-223 demonstrates a significantly improved safety profile with reduced risk of myelosuppression and bone marrow toxicity. It is being developed primarily by TB Alliance and is currently in Phase 2 clinical trials for pulmonary tuberculosis[1][2][4][6][8].

Other names

CARBAMIC ACID, N-(((5S)-3-(3-FLUORO-4-(2-OXA-6-AZASPIRO(3.3)HEPT-6-YL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, METHYL ESTER2071265-08-0B4RS1V5YSPB-4RS1V5YSPB 4RS1V5YSP